The Brexit Health Alliance is again warning that medicines supply in the UK is in danger of being disrupted if the issue of co-operative regulation is not addressed during Brexit negotiations. More: Brexit Alliance calls for Brexit deal on medicines
read moreSanthera’s attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors. More: EU advisors reject Santhera’s Raxone for muscular
read moreUS regulators have cleared the use of Novartis group Advanced Accelerator Applications’ Lutathera to treat certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs). More: US clears new option for gastroenteropancreatic tumours Source: News
read moreThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder. More: Seven
read more© 1994 - 2026 B.M. Pharmaceuticals